The 2019 Benchmarking Pharma Partnering in Europe report outlines how deals are flowing in Europe, noting partnerships in this region don’t come without their costs.

A look at the risks and rewards in the European market

We analyzed 43 pharmaceutical licensing deals between January 2012 and August 2019, in which Europe was the major territory for a foreign partner.
Some of the details in the report include:

• • Total deal size;
• • Upfront and equity payments;
• • Development, commercial and total milestones;
• • Royalties;
• • Number of products in a deal;
• • Therapeutic area and deal value;
• • Phase of development and deal value;
  
  

Discover if partnering in China will be worthwhile for your company.

Get the PDF:
What's a Deal Worth? Benchmarking Pharma Partnering in Europe